By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian molecular diagnostic firm DiaGenic, which has developed quantitative real-time PCR-based blood tests for Alzheimer's disease and breast cancer, said today that it has raised NOK70 million ($12.1 million) in a private placement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.